Navigation Links
GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies
Date:7/8/2008

NEW ROCHELLE, N.Y., July 8 /PRNewswire/ -- Biotech and pharmaceutical firms are developing a host of new technologies designed to streamline the complicated drug discovery process, reports Genetic Engineering and Biotechnology News (GEN). Most successful approaches rely on a combination of high-throughput screening methods, miniaturization techniques, and advanced data-analysis tools, according to an article in the July issue (http://www.genengnews.com/articles/chitem.aspx?aid=2527) of GEN.

"The key goal for companies trying to develop new drugs is to find the best series of compounds that will optimize their chances of turning promising hits into even more promising leads," notes John Sterling, Editor in Chief of GEN.

Merck, for example, tries to make certain that its scientists work on physiologically relevant targets and assays during early-stage drug discovery research. For target identification the company uses RNAi technology in human cell lines. Multiparametric assays then generate biological activity profiles that can often provide valuable insight into complex disease models.

Pharmacopeia's screening platform is based on its ECLiPS(R) (encoded combinatorial libraries on polymeric support) technology. Three steps are involved in the firm's screening process. A primary high-throughput approach screens eluate from multiple beads. A follow-up protocol screens single bead eluates from those sublibraries, which demonstrate activity in the assay. Finally, company scientists submit beads for a decoding process, which is how they identify the structure of compounds in the active wells in step two.

Also discussed in the GEN article is drug discovery activities taking place at GlaxoSmithKline, Fujifilm, Archemix, and the Southern Research Institute.

For a copy of the July issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering and Biotechnology News (http://www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News

Ph: (914) 740-2196, jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering and Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Galaxy Nutritional Foods Reports FY2008 Results
2. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/7/2016)... San Diego (PRWEB) , ... December 07, 2016 ... ... safety data from its phase I/II dose escalation and expansion clinical trial for ... 2016 in Vienna, Austria. The purpose of the trial was to determine the ...
Breaking Biology Technology:
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):